GlaxoSmithKline's US fat buster's first-quarter sterling sales failed to get into double figures.
Alli recorded sales of just £9.0 million (€11.2 million) in the first quarter of this year. GSK put this down to inventory issues.
US market demand for Alli was still strong, the company said, with underlying demand estimated by retail data to have been worth £35 million in consumer sales.
Alli generated sales of around £160 million in the nine-month period between its launch last June and the end of the first quarter.
Alli recorded sales of just £9.0 million (€11.2 million) in the first quarter of this year. GSK put this down to inventory issues.
US market demand for Alli was still strong, the company said, with underlying demand estimated by retail data to have been worth £35 million in consumer sales.
Alli generated sales of around £160 million in the nine-month period between its launch last June and the end of the first quarter.
Let's hope these sales are good enough to prevent Steve Burton from having another accident!
No comments:
Post a Comment